CGI Pharmaceuticals is
dedicated to the discovery and development of breakthrough small molecule
therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory
disease (AAID) indications. The Company’s fully integrated drug discovery
infrastructure comprises proprietary kinase biology and chemistry, extensive
lead generation and optimization capabilities, as well as drug
metabolism/pharmacokinetics (DMPK) expertise. Utilizing its comprehensive
chemistry capabilities, CGI has generated a proprietary small molecule kinase
inhibitor library of over 50,000 compounds (all compounds designed and
synthesized by CGI).
include: Bessemer Venture Partners,
Polaris Venture Partners, Lux Capital and Venrock.